Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
Completed
The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2018
Locations: Long Island Vitreoretinal Consultants, Great Neck, New York +2 locations
Conditions: Macular Edema, Central Retinal Vein Occlusion
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Terminated
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2018
Locations: Not set, Great Neck, New York
Conditions: Multiple Myeloma
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Completed
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2018
Locations: Not set, New York, New York
Conditions: Multiple Myeloma
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Completed
This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of moderately emetogenic oxaliplatin-based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2017
Locations: GSK Investigational Site, Bronx, New York
Conditions: Nausea and Vomiting, Chemotherapy-Induced
Dexamethasone as an Immediate Intervention
Withdrawn
To determine if a single dose of dexamethasone (5 mg) administered in the first 12 hours following a potentially traumatic event alters a) cortisol and FKBP5 RNA the next day in the periphery measured in saliva; b) FKBP5 methylation by 1 month; c) executive functioning and emotion regulation functioning; d) psychophysiological (heart rate, respiration, skin conductance) in response cued reminders of the trauma; e) enhances the likelihood of remission of PTSD symptom severity.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/12/2017
Locations: New York University Medical Center, New York, New York
Conditions: Trauma
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Terminated
This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2017
Locations: Advanced Oncology Associates, Armonk, New York +3 locations
Conditions: Lymphoma, Follicular
Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis
Withdrawn
Chronic lumbosacral radiculopathy secondary to lumbar spinal stenosis affects a large number of individuals, and there is a general lack of consensus in the medical community in terms of effective treatments for this problem. By assessing the relative efficacy of transforaminal epidural injections of particulate and nonparticulate steroids, this study attempts to further define the appropriate conservative management of painful unilateral radiculopathies due to unilateral lumbar foraminal stenos... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
12/04/2017
Locations: Hospital for Special Surgery, New York, New York
Conditions: Lumbar Spinal Stenosis
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Completed
This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2017
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
Completed
GW679769 may affect liver enzymes that metabolize dexamethasone and ondansetron. This study is designed to test the safety and the extent of the GW679769 affect on dexamethasone and ondansetron levels in humans.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/08/2017
Locations: GSK Investigational Site, Buffalo, New York
Conditions: Nausea and Vomiting, Chemotherapy-Induced
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Terminated
RATIONALE: Calcitriol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. Dexamethasone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with dexamethasone may be an effective treatment for prostate cancer that did not respond to hormone therapy . PURPOSE: This phase II trial is studying how well giving calcitriol together with dexamethasone works in treating patients with prostate cancer t... Read More
Gender:
MALE
Ages:
120 years and below
Trial Updated:
10/17/2017
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Prostate Cancer
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Completed
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2017
Locations: Columbia University, New York, New York +1 locations
Conditions: Amyloidosis, Systemic Light Chain Amyloidosis
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Completed
Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2017
Locations: Roswell Park Cancer Institute, Buffalo, New York +4 locations
Conditions: Multiple Myeloma